doi: 10.3389/fimmu.2024.1464329 Received 13 July 2024 Accepted 17 September 2024 Published 07 October 2024 Volume 15 - 2024 Edited by Philip Calder, University of Southampton, United Kingdom Reviewed by Md Tajmul, National Institute of Diabetes and Digestive and Kidney Diseases (NIH), United States Isaacson Bababode Adelani, Johns Hopkins Medicine, United States Updates Copyright 2024 Munteanu, Mrza and Papuc
Taking action on childhood obesity
Research findings suggest a potential link between the physical manifestations of PCOS and adverse psychological effects, including decreased self-esteem and increased anxiety in pubescent females, which may exacerbate mood disorders and reduce the overall quality of life in adolescent patients with PCOS
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
